Litigation Details for Gilead Sciences, Inc. v. Lupin Ltd. (D. Del. 2022)
✉ Email this page to a colleague
Gilead Sciences, Inc. v. Lupin Ltd. (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-05-09 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | CIPLA LIMITED | ||
| Patents | 10,385,067; 10,548,846; 9,708,342 | ||
| Attorneys | Andrew O. Larsen | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Lupin Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Gilead Sciences, Inc. v. Lupin Ltd. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-05-09 | 1 | Complaint | expiration of U.S. Patent Nos. 9,708,342, 10,385,067, and 10,548,846 (collectively, “the Patents-In-Suit”). … the ’342 patent and holds title to the ’342 patent. 41. The ’342 patent claims, among…of the ’067 patent and holds title to the ’067 patent. 44. The ’067 patent claims, among…of the ’846 patent and holds title to the ’846 patent. 47. The ’846 patent claims, among…Defendant has infringed the ’342 patent, the ’067 patent, and/or the ’846 patent under 35 U.S.C. § 271(e)(2 | External link to document |
| 2023-11-15 | 167 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,708,342 B2; 10,385,067 B2; 10,548,… 9 May 2022 1:22-cv-00615 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-11-16 | 171 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,708,342 B2; 10,385,067 B2; 10,548,… 9 May 2022 1:22-cv-00615 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-05-09 | 3 | ANDA Form | Expiration of Patent: U.S. Patent No. 9,708,342: June 19, 2035. U.S. Patent No. 10,385,067: June 19, 2035… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2035. U.S. Patent No. 10,548,846: November 8, 2036.Thirty Month Stay Deadline: 8/7/2025. (srs) (Entered… 9 May 2022 1:22-cv-00615 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-05-09 | 4 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,708,342 B2 ;10,385,067 B2 ;10,548,… 9 May 2022 1:22-cv-00615 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-01-06 | 58 | Notice of Service | Invalidity Contentions Regarding U.S. Patent Nos. 10,548,846, 10,385,067 and 9,708,342 filed by Lupin Ltd.… 9 May 2022 1:22-cv-00615 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
